Cure the Coronavirus Act

Bill: 116-hr-6019
Sponsor: full_name: Rep. Jeffries, Hakeem S. [D-NY-8]
Introduced: 2020-02-28
Policy area: Health
Subjects: Cardiovascular and respiratory health

Drug safety, medical device, and laboratory regulation

Emergency medical services and trauma care

Infectious and parasitic diseases
Latest action: action_date: 2020-02-28
text: Referred to the House Committee on Energy and Commerce.

Summaries:
action_date: 2020-02-28
action_desc: Introduced in House
text: <p><b>Cure the Coronavirus Act</b></p> <p>This bill expands the tropical disease priority review voucher program to include COVID-19 (a respiratory disease caused by a novel coronavirus), thereby providing manufacturers with incentives for development of a vaccine.</p>

tv_txt: I 116th CONGRESS 2d Session H. R. 6019 IN THE HOUSE OF REPRESENTATIVES February 28, 2020 Mr. Jeffries (for himself, Mr. King of New York , Mr. Cárdenas , and Ms. Herrera Beutler ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To expand the tropical disease product priority review voucher program to encourage treatments for coronavirus.

1. Short title This Act may be cited as the Cure the Coronavirus Act . 2. Expanding tropical disease product priority review voucher program to encourage treatments for coronavirus Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360n(a)(3) ) is amended— (1) by redesignating subparagraph (S) as subparagraph (T); and (2) by inserting after subparagraph (R) the following: (S) The 2019 novel coronavirus (COVID–19). .